0 works0 citations0 h-index

Donald Richards

Cedars-Sinai Medical Center(US)Pennsylvania State University(US)The University of Texas at Tyler(US)Texas Oncology(US)Sarah Cannon(US)Janssen (United States)(US)

Publications by Year

Research Areas

Colorectal Cancer Treatments and Studies, Lung Cancer Treatments and Mutations, Cancer Treatment and Pharmacology, Pancreatic and Hepatic Oncology Research, HER2/EGFR in Cancer Research

Most-Cited Works

→ Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial(2015)1,174 cited
→ Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set(2021)895 cited
→ Randomized, Controlled Trial of Irinotecan Plus Infusional, Bolus, or Oral Fluoropyrimidines in First-Line Treatment of Metastatic Colorectal Cancer: Results From the BICC-C Study(2007)854 cited
→ Pilot Study Using Molecular Profiling of Patients' Tumors to Find Potential Targets and Select Treatments for Their Refractory Cancers(2010)632 cited
→ Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735(2009)585 cited

→ Randomized Phase III Study of Docetaxel Compared With Paclitaxel in Metastatic Breast Cancer(2005)

547 cited

→ Phase III Trial Comparing Doxorubicin Plus Cyclophosphamide With Docetaxel Plus Cyclophosphamide As Adjuvant Therapy for Operable Breast Cancer(2006)537 cited

→ Phase III Study of Cisplatin, Etoposide, and Concurrent Chest Radiation With or Without Consolidation Docetaxel in Patients With Inoperable Stage III Non–Small-Cell Lung Cancer: The Hoosier Oncology Group and U.S. Oncology(2008)493 cited

→ Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial(2013)465 cited

→ PointBreak: A Randomized Phase III Study of Pemetrexed Plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab Versus Paclitaxel Plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB or IV Nonsquamous Non–Small-Cell Lung Cancer(2013)373 cited